Cover Image

Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma

Allogeneic hematopoietic cell transplantation (alloHCT) is an effective treatment for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), but the contribution of the conditioning regimen is still unclear. Here we present a retrospective single-center study using conditioning with in...

Full description

Saved in:
Bibliographic Details
Main Authors: Krämer, Isabelle (Author) , König, Laila (Author) , Luft, Thomas (Author) , Hegenbart, Ute (Author) , Schönland, Stefan (Author) , Eichkorn, Tanja (Author) , Stadtherr, Peter (Author) , Selberg, Lorenz (Author) , Müller-Tidow, Carsten (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 13 February 2025
In: Bone marrow transplantation
Year: 2025, Volume: 60, Issue: 5, Pages: 581-586
ISSN:1476-5365
DOI:10.1038/s41409-025-02522-4
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41409-025-02522-4
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41409-025-02522-4
Get full text
Author Notes:Isabelle Krämer, Laila König, Thomas Luft, Ute Hegenbart, Stefan Schönland, Tanja Eichkorn, Peter Stadtherr, Lorenz Selberg, Carsten Müller-Tidow and Peter Dreger
Description
Summary:Allogeneic hematopoietic cell transplantation (alloHCT) is an effective treatment for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL), but the contribution of the conditioning regimen is still unclear. Here we present a retrospective single-center study using conditioning with intermediate-dose total body irradiation (TBI) and fludarabine for alloHCT in PTCL. Forty-seven patients underwent alloHCT for PTCL between 2010 and 2023 after conditioning with fludarabine and intermediate-dose TBI (8 Gy in 87% of the cases). In most patients alloHCT was administered as part of second-line therapy, in 22 (47%) patients after having been primary refractory, and 21 (45%) of the patients were chemoresistant at alloHCT. With a median follow-up of 5.5 years, 5-year progression-free survival (PFS), overall survival, relapse incidence, and non-relapse mortality were 61%, 65%, 24%, and 15%, respectively. The 5-year PFS of patients transplanted with stable disease and progressive disease was 57% and 26%, respectively. Of 11 relapses, only 2 (18%) occurred beyond 6 months post transplant, and no relapse was observed after onset of chronic graft-versus-host disease. AlloHCT with intermediate-dose TBI/fludarabine conditioning is associated with a favorable toxicity/efficacy profile and can provide durable survival in a substantial fraction of patients with PTCL including those with poorly controlled disease at transplant.
Item Description:Online veröffentlicht: 13. Februar 2025
Gesehen am 24.07.2025
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/s41409-025-02522-4

Similar Items